HUP0301711A2 - Elágazó láncú lipofil molekulák származékai és alkalmazásuk - Google Patents

Elágazó láncú lipofil molekulák származékai és alkalmazásuk

Info

Publication number
HUP0301711A2
HUP0301711A2 HU0301711A HUP0301711A HUP0301711A2 HU P0301711 A2 HUP0301711 A2 HU P0301711A2 HU 0301711 A HU0301711 A HU 0301711A HU P0301711 A HUP0301711 A HU P0301711A HU P0301711 A2 HUP0301711 A2 HU P0301711A2
Authority
HU
Hungary
Prior art keywords
mono
group
tumors
general formula
well
Prior art date
Application number
HU0301711A
Other languages
English (en)
Inventor
Eliezer Beit-Yannai
Alexander Kozak
Michael Polyak
Dalia Reznitsky-Cohen
Alexander Senderikhin
Marina Vinnikova
Original Assignee
D-Pharm Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by D-Pharm Ltd. filed Critical D-Pharm Ltd.
Publication of HUP0301711A2 publication Critical patent/HUP0301711A2/hu
Publication of HUP0301711A3 publication Critical patent/HUP0301711A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/11—Esters of phosphoric acids with hydroxyalkyl compounds without further substituents on alkyl
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/091—Esters of phosphoric acids with hydroxyalkyl compounds with further substituents on alkyl
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/10—Phosphatides, e.g. lecithin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Communicable Diseases (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Fats And Perfumes (AREA)
  • Cosmetics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

A találmány (I) általános képletű, elágazó láncú lipofil molekulákfoszforszármazékaira és gyógyszerészetileg elfogadható sóikra,valamint alkalmazásukra vonatkozik. A vegyületek biológiai gátakpermeabilitásának fokozására és így tumorok növekedésének gátlásáravalamint terápiás és diagnosztikai szerek tumorokba történőjuttatására alkalmazhatók. Az képletben R1 és R2 jelentése azonos vagyeltérő, telített vagy telítetlen alifás, 2-30 szénatomos szénlánc, R3jelentése A-[CH2]m-B-[CH2]n-C-[CH2]p-D általános képletű csoport, aholm, n és p értéke egymástól függetlenül 0-12, és A, B, C és D jelentéseegymástól függetlenül kovalens kötés, amino-, amido-, oxigén-, tio-,karbonil-, karboxil-, oxikarbonil-, tiokarbonil-, foszfát-,aminofoszfát-, mono-, di- vagy triaminofoszfát-csoport, azzal afeltétellel, hogy két oxigénatom nem kapcsolódhat egymáshoz; Z1 és Z2jelentése azonos vagy eltérő, hiányzik vagy egymástól függetlenül (a)hidrogén-, nátrium-, lítium-, kálium-, ammónium-, mono-, di , tri- éstetraalkil-ammónium-ion közül valamelyik, (b) a foszfocsoporttalegyütt glicerin, kolin, etanolamin, miozit, szerin, mono- vagyoligoszacharidok foszfoészterét képezi. Ó
HU0301711A 2000-08-03 2001-08-01 Derivatives of branched-chain lipophilic molecules and uses thereof HUP0301711A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IL13767200A IL137672A0 (en) 2000-08-03 2000-08-03 Derivatives of branched-chain lipophilic molecules and uses thereof
PCT/IL2001/000713 WO2002011666A2 (en) 2000-08-03 2001-08-01 Derivatives of branched-chain lipophilic molecules and uses thereof

Publications (2)

Publication Number Publication Date
HUP0301711A2 true HUP0301711A2 (hu) 2003-09-29
HUP0301711A3 HUP0301711A3 (en) 2007-05-29

Family

ID=11074480

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0301711A HUP0301711A3 (en) 2000-08-03 2001-08-01 Derivatives of branched-chain lipophilic molecules and uses thereof

Country Status (16)

Country Link
US (2) US7186703B2 (hu)
EP (1) EP1305322B1 (hu)
JP (1) JP2004505898A (hu)
KR (1) KR100801207B1 (hu)
CN (1) CN100467476C (hu)
AT (1) ATE455120T1 (hu)
AU (2) AU8004301A (hu)
BR (1) BR0112835A (hu)
CA (1) CA2416808C (hu)
CZ (1) CZ2003208A3 (hu)
DE (1) DE60141074D1 (hu)
ES (1) ES2338987T3 (hu)
HU (1) HUP0301711A3 (hu)
IL (1) IL137672A0 (hu)
NZ (1) NZ523664A (hu)
WO (1) WO2002011666A2 (hu)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6518311B2 (en) * 1997-07-09 2003-02-11 D-Pharm Ltd. Use of branched-chain fatty acids and derivatives thereof for the treatment of pain
US7582678B2 (en) 1997-07-09 2009-09-01 D-Pharm Limited Use of branched-chain fatty acids and derivatives thereof for the treatment of pain
CA2425215C (en) * 2000-10-10 2009-12-29 University Of North Carolina At Chapel Hill Compositions and methods for enhancing paracellular permeability across epithelial and endothelial barriers
AU2003211052A1 (en) 2002-02-11 2003-09-04 Vertex Pharmaceuticals Incorporated Phospholipids as caspase inhibitor prodrugs
AU2003224087B2 (en) 2002-04-18 2009-03-05 Opko Pharmaceuticals, Llc. Means and methods for the specific inhibition of genes in cells and tissue of the CNS and/or eye
US7148342B2 (en) 2002-07-24 2006-12-12 The Trustees Of The University Of Pennyslvania Compositions and methods for sirna inhibition of angiogenesis
WO2005051298A2 (en) 2003-11-19 2005-06-09 Metabasis Therapeutics, Inc. Novel phosphorus-containing thyromimetics
US8153435B1 (en) 2005-03-30 2012-04-10 Tracer Detection Technology Corp. Methods and articles for identifying objects using encapsulated perfluorocarbon tracers
US20090232879A1 (en) 2005-05-26 2009-09-17 Metabasis Therapeutics, Inc. Thyromimetics for the Treatment of Fatty Liver Diseases
AU2006249347A1 (en) * 2005-05-26 2006-11-30 Metabasis Therapeutics, Inc. Novel phosphorus-containing thyromimetics
US8703179B2 (en) * 2006-05-11 2014-04-22 Kimberly-Clark Worldwide, Inc. Mucosal formulation
EP2180788B1 (en) * 2007-08-10 2016-12-21 Basil Rigas Anti-inflammatory compounds and uses thereof
EP2262512A1 (en) * 2008-02-28 2010-12-22 Henry Ford Health System Compositions and methods for using stromal cells to enhance treatment of central nervous system injuries
WO2010107487A2 (en) * 2009-03-18 2010-09-23 Wu Nian Lipid-drug conjugates for drug delivery
JP5853869B2 (ja) * 2012-06-07 2016-02-09 日油株式会社 ホスホリルコリン基含有化合物及びその製造法
KR20190104524A (ko) 2016-11-21 2019-09-10 바이킹 테라퓨틱스 인코포레이티드 당원축적질환의 치료 방법
EP3634426A4 (en) 2017-06-05 2021-04-07 Viking Therapeutics, Inc. COMPOSITIONS FOR THE TREATMENT OF FIBROSIS
EA202091979A1 (ru) 2018-03-22 2021-06-22 Вайкинг Терапьютикс, Инк. Кристаллические формы и способы получения кристаллических форм соединения
US12102646B2 (en) 2018-12-05 2024-10-01 Viking Therapeutics, Inc. Compositions for the treatment of fibrosis and inflammation

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3006946A (en) 1953-03-04 1961-10-31 Union Carbide Corp Production of heterocyclic phosphoruscontaining compounds and products
US3260688A (en) 1962-08-10 1966-07-12 Toyo Koatsu Ind Inc Resin compositions for producing cellular masses and process for producing a cellular product
US3260668A (en) 1964-11-04 1966-07-12 Dow Chemical Co Alkaline scale control in saline water conversion equipment
DE2038829C3 (de) * 1970-08-05 1975-11-13 Chemische Werke Huels Ag, 4370 Marl Zusatzmittel zu Mörtel oder Beton auf Zementbasis
LU65735A1 (hu) * 1972-07-17 1974-01-28
DE2930756A1 (de) * 1979-07-28 1981-02-26 Cassella Ag Klotzhilfsmittel und verfahren zum faerben von cellulosefasern bzw. gemischen von cellulosefasern zusammen mit synthesefasern mit schwefel-, schwefelkuepen-, kuepen- und reaktivfarbstoffen
JPS6038363B2 (ja) * 1979-11-27 1985-08-31 ライオン株式会社 ヘアリンス剤
JPS5716064A (en) * 1980-07-04 1982-01-27 Dai Ichi Kogyo Seiyaku Co Ltd Dye dispersion
JPS57112317A (en) * 1980-12-29 1982-07-13 Lion Corp Hairdressing agent composition
JPS5984824A (ja) * 1982-11-08 1984-05-16 Takeda Chem Ind Ltd 抗腫瘍剤
JPS6072829A (ja) * 1983-09-29 1985-04-24 Kao Corp ベシクル用組成物
JPS60184092A (ja) * 1984-03-01 1985-09-19 Kao Corp リン酸エステルおよびその製法
JPH0832832B2 (ja) 1984-03-09 1996-03-29 花王株式会社 加熱瀝青質用添加剤
US4670575A (en) * 1984-06-05 1987-06-02 Kao Corporation Process for purification of phosphoric mono esters
JPS61129189A (ja) * 1984-11-28 1986-06-17 Kao Corp リン酸エステルまたはその塩の精製方法
US4736051A (en) * 1985-03-20 1988-04-05 Kao Corporation Process for the preparation of an alkali metal salt of a diester phosphoric acid
US4751320A (en) * 1985-11-27 1988-06-14 Kao Corporation Phosphoric ester and process for producing same
CA1338627C (en) 1985-12-04 1996-10-01 Hansjorg Eibl Pharmaceuticals based on phosphoric acid esters for use in tumor therapy, and process for their preparation
US5916884A (en) * 1985-12-04 1999-06-29 Max-Planck-Gesellschaft Zur Foederung Der Wissenschaften Compositions containing a mixture of phosphorus compounds and alkylglycerols
JPS62177008A (ja) * 1986-01-29 1987-08-03 Kao Corp 共重合体の製造法
JPS63122775A (ja) 1986-11-12 1988-05-26 Kao Corp 油ゲル化剤
JPH01290604A (ja) * 1988-05-18 1989-11-22 Dai Ichi Kogyo Seiyaku Co Ltd 水中崩壊性良好な農薬粒剤
WO1989011299A1 (en) 1988-05-18 1989-11-30 State Of Oregon Acting By And Through The State Bo Method for delivery of therapeutic agents to target brain tissue using monoclonal antibody conjugates
US5059415A (en) 1989-02-21 1991-10-22 The State Of Oregon Acting By And Through The Oregon State Board Of Higher Education On Behalf Of Oregon Health Method for diagnostically imaging lesions in the brain inside a blood-brain barrier
FR2677360B1 (fr) * 1991-06-05 1995-04-14 Atta Composes amphiphiles perfluoroalkyles du phosphore, leurs preparations et leurs applications notamment dans le domaine biomedical.
US5846516A (en) * 1992-06-03 1998-12-08 Alliance Pharmaceutial Corp. Perfluoroalkylated amphiphilic phosphorus compounds: preparation and biomedical applications
JP2710900B2 (ja) * 1992-09-02 1998-02-10 株式会社ディ・ディ・エス研究所 酸性官能基を有する脂質誘導体及び同誘導体によって被覆された微粒子キャリヤー
US5491004A (en) * 1994-05-26 1996-02-13 Henkel Corporation Process for applying a low soiling fiber finish
DE69623214T2 (de) * 1995-09-29 2003-04-30 Dainippon Ink And Chemicals, Inc. Verfahren zur Herstellung von Polyestermischungen auf Basis von Polylactiden
JP3747091B2 (ja) * 1996-03-22 2006-02-22 株式会社クラブコスメチックス アポトーシス誘導剤
US6030961A (en) * 1997-03-11 2000-02-29 Bar-Ilan Research & Development Co., Ltd. Oxyalkylene phosphate compounds and uses thereof
ZA984836B (en) * 1997-06-04 1999-06-04 Biocompatibles Ltd Compounds
ZA984837B (en) * 1997-06-04 1999-06-04 Biocompatibles Ltd Phosphate compounds
IL121269A0 (en) 1997-07-09 1998-01-04 Dpharm Ltd Compositions and methods for reversibly increasing permeability of biomembranes
IL121268A0 (en) * 1997-07-09 1998-01-04 Dpharm Ltd Branched chain fatty acids their derivatives and use in the treatment of central nervous system disorders
JP2000053897A (ja) * 1998-08-07 2000-02-22 Kao Corp インクジェット記録用水系インク

Also Published As

Publication number Publication date
CA2416808A1 (en) 2002-02-14
CA2416808C (en) 2011-11-22
CN1633440A (zh) 2005-06-29
KR100801207B1 (ko) 2008-02-05
CN100467476C (zh) 2009-03-11
BR0112835A (pt) 2003-10-21
HUP0301711A3 (en) 2007-05-29
US20070135381A1 (en) 2007-06-14
KR20030024823A (ko) 2003-03-26
DE60141074D1 (de) 2010-03-04
IL137672A0 (en) 2001-10-31
CZ2003208A3 (cs) 2003-10-15
EP1305322B1 (en) 2010-01-13
AU2001280043B2 (en) 2007-05-24
EP1305322A4 (en) 2005-04-13
JP2004505898A (ja) 2004-02-26
US7186703B2 (en) 2007-03-06
EP1305322A2 (en) 2003-05-02
US7687483B2 (en) 2010-03-30
AU2001280043B8 (en) 2002-02-18
ES2338987T3 (es) 2010-05-14
WO2002011666A2 (en) 2002-02-14
ATE455120T1 (de) 2010-01-15
AU8004301A (en) 2002-02-18
WO2002011666A3 (en) 2002-07-11
US20030186897A1 (en) 2003-10-02
NZ523664A (en) 2004-07-30

Similar Documents

Publication Publication Date Title
HUP0301711A2 (hu) Elágazó láncú lipofil molekulák származékai és alkalmazásuk
Prokai et al. Targeting drugs to the brain by redox chemical delivery systems
Bartholeyns et al. Involvement of histamine in growth of mouse and rat tumors: antitumoral properties of monofluoromethylhistidine, an enzyme-activated irreversible inhibitor of histidine decarboxylase
ES2719091T3 (es) Terapia de combinación con un inhibidor mitótico
US20120283328A1 (en) Photosensitizer composition for treating skin disorders
ES2161085T3 (es) Formulaciones que contienen oxaliplatino.
AU7115191A (en) Biphenylylaliphathylamino compounds, their use as antihypertensives, pharmaceutical compositions and processes for their manufacture
WO2002087465A3 (en) Compositions and methods of double-targeting virus infections and cancer cells
Pegg et al. Effects of aliphatic diamines on rat liver ornithine decarboxylase activity
JP7144554B2 (ja) 患者における転移性癌の有効な治療のための組合せ
RU2007138582A (ru) Пероральные дозированные формы производных гемцитабина
NO20025739D0 (no) Forbindelser med en sulfonamidgruppe og farmasöytiske preparater som inneholder disse forbindelsene
JP2002503714A5 (hu)
CN103599069A (zh) 一种由pH敏感性多肽修饰的靶向脂质体
EP0338058A4 (en) Phosphatidyl treatment of viral disease
WO2001034614A3 (en) Compositions and methods for double-targeting virus infections and targeting cancer cells
BR0013613A (pt) Preparação farmaceuticamente estável de oxaliplatina para administração parenteral
RU2013105783A (ru) Парентеральные составы производных элацитарабина
BR0009771A (pt) Utilização de derivados de bisindóis indigóides capazes de penetrarem na membrana de células
Kestell et al. Disposition of amsacrine and its analogue 9-({; 2-methoxy-4-[(methylsulfonyl)-amino] phenyl} amino)-N, 5-dimethyl-4-acridinecarboxamide (CI-921) in plasma, liver, and lewis lung tumors in mice
MX2007009312A (es) Preparaciones inyectables de diclofenaco y sus sales farmaceuticamente aceptables.
EA200300427A1 (ru) Противоопухолевая терапия, включающая производные дистамицина
ES2176009T3 (es) Utilizacion de cloruro de sodio para reducir la toxicidad gastrointestinal de los derivados de la competencia.
CA2393487A1 (en) Pharmaceutical preparation for the treatment of oncoses
Heby et al. Effects of methylglyoxal-bis (guanylhydrazone) on polyamine metabolism in spleens of mice with disseminated L1210 lymphoid leukemia

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees